103 related articles for article (PubMed ID: 29172837)
1. Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand.
Deerochanawong C; Kosachunhanun N; Chotikanokrat P; Permsuwan U
Curr Med Res Opin; 2018 Feb; 34(2):369-375. PubMed ID: 29172837
[TBL] [Abstract][Full Text] [Related]
2. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
3. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
4. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
6. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
7. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
Balaji V; Balaji MS; Alexander C; Srinivasan A; Suganthi SR; Thiyagarajah A; Seshiah V
Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
[TBL] [Abstract][Full Text] [Related]
8. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
Shafie AA; Gupta V; Baabbad R; Hammerby E; Home P
Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
11. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
Liebl A; Mohan V; Yang W; Strojek K; Linjawi S
Drugs R D; 2018 Mar; 18(1):27-39. PubMed ID: 29468559
[TBL] [Abstract][Full Text] [Related]
12. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
[TBL] [Abstract][Full Text] [Related]
14. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
Nobels F; D'Hooge D; Crenier L
Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
[TBL] [Abstract][Full Text] [Related]
16. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
Lezzar A; Ayad F; Dahaoui A; Salah-Mansour A; Berrouiguet AY
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
Guo L; Chen L; Chang B; Yang L; Liu Y; Feng B
Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
Valentine WJ; Pollock RF; Plun-Favreau J; White J
Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
